trending Market Intelligence /marketintelligence/en/news-insights/trending/gbltbls9duzq0a-dm25cra2 content esgSubNav
In This List

Gilead CEO's total compensation rises to $15.4M in 2017

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Gilead CEO's total compensation rises to $15.4M in 2017

Gilead Sciences Inc. paid President and CEO John Milligan about $15.4 million in total remuneration during 2017, up from about $13.9 million in 2016.

Milligan pocketed almost $1.55 million in base salary and $3.24 million in bonus payments, the company stated in a filing to the U.S. Securities and Exchange Commission.

That compares to $1.5 million in base salary and $2.61 million in bonus payments in 2016.

The California-based pharmaceutical giant's CEO received $4.89 million from stock awards and almost $5.75 million from option awards in 2017. In 2016, Milligan received about $4.35 million from stock awards and about $5.5 million from option awards.

Gilead's compensation committee had previously approved equity awards worth $11.5 million for Milligan in 2017 at its February 2017 meeting, compared to $11 million the previous year.

The ratio of Milligan's annual total compensation compared to Gilead's median employee's total annual compensation for fiscal year 2017 is 94 to 1.